



## ALLERGY & IMMUNOLOGY INFUSION ORDER FORM

P: 240.200.4464 F: 240.892.3005

**PATIENT INFORMATION:** Fax completed form, insurance information, and clinical documentation to 240.892.3005

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_

### MEDICAL INFORMATION

Patient Weight: \_\_\_\_\_ lbs./kg. (required) Allergies: \_\_\_\_\_

### THERAPY ORDER

Diagnosis	Infusion Orders	Refills
<input type="checkbox"/> Persistent Asthma (ICD-10 Code: _____) <input type="checkbox"/> Chronic Idiopathic Urticaria (ICD-10 Code: _____) <input type="checkbox"/> Nasal Polyps (ICD-10: _____)	<input type="checkbox"/> <b>Xolair</b> 75mg Sub-Q <input type="checkbox"/> <b>Xolair</b> 150mg Sub-Q <input type="checkbox"/> <b>Xolair</b> 225mg Sub-Q <input type="checkbox"/> <b>Xolair</b> 300mg Sub-Q <input type="checkbox"/> <b>Xolair</b> 375mg Sub-Q <input type="checkbox"/> <b>Xolair</b> 450mg Sub-Q <input type="checkbox"/> <b>Xolair</b> 525mg Sub-Q <input type="checkbox"/> <b>Xolair</b> 600mg Sub-Q  <input type="checkbox"/> <b>Cinqair</b> 3mg/kg IV every 4 weeks <input type="checkbox"/> <b>Fasenra</b> initial dose: 30mg Sub-Q every 4 weeks for the first 3 doses followed by 30mg Sub-Q every 8 weeks thereafter <input type="checkbox"/> <b>Fasenra</b> continuing therapy: 30mg Sub-Q every 8 weeks <input type="checkbox"/> <b>Nucala</b> 100mg Sub-Q every 4 weeks <input type="checkbox"/> <b>Nucala</b> 300mg Sub-Q every 4 weeks <input type="checkbox"/> <b>Tezspire</b> 210mg Sub-Q every 4 weeks	<input type="checkbox"/> _____ <input type="checkbox"/> X 1 year
<input type="checkbox"/> Severe Asthma with Eosinophilic phenotype. (ICD-10: _____) <input type="checkbox"/> Severe Granulomatosis with Polyangiitis. (ICD-10 Code: _____)	<input type="checkbox"/> <b>Immunoglobulin:</b> <input type="checkbox"/> <b>IV</b> <input type="checkbox"/> <b>Sub-Q</b> _____ mg/kg <b>OR</b> _____ gm/kg x _____ day(s) <b>OR</b> divided over _____ day(s) Frequency: Every _____ weeks <b>OR</b> _____ Brand (Active Infusions to choose if not indicated): _____ Additional Ig orders: _____	<input type="checkbox"/> _____ <input type="checkbox"/> X 1 year
<input type="checkbox"/> Common Variable Immunodeficiency (ICD-10: _____) <input type="checkbox"/> Other: _____ (ICD-10 Code: _____)		<input type="checkbox"/> _____ <input type="checkbox"/> X 1 year

#### Premedication Orders:

Tylenol: ☐ 1000mg PO ☐ 500mg PO

Antihistamine: ☐ Diphenhydramine 25mg PO ☐ Loratadine 10mg PO ☐ Cetirizine 10mg PO ☐ Other: \_\_\_\_\_

Additional premedication: ☐ Solu-Medrol \_\_\_\_\_ mg IVP ☐ Solu-Cortef \_\_\_\_\_ mg IVP ☐ Other: \_\_\_\_\_

Please provide patient's demographic information, insurance information, medication list, and clinical notes. Active Infusions will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and assist them in enrolling in any available co-pay assistance programs as needed/applicable. Thank you for the referral.

### PROVIDER INFORMATION

Provider Name: \_\_\_\_\_ Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Provider NPI: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Contact Person: \_\_\_\_\_

ACTIVEINFUSIONS.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.



**COMPREHENSIVE SUPPORT FOR  
ALLERGY / IMMUNOLOGY THERAPY  
P: 240-200-4464 F: 240-892-3005**

**PATIENT INFORMATION:**

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_

**REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING AND INSURANCE APPROVAL**

- ☐ Include signed and completed order (MD/prescriber to complete previous page)
- ☐ Include patient demographic information and insurance information
- ☐ Include patient's medication list
- ☐ Supporting clinical notes (H&P) to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy
  - ☐ Please indicate any tried and failed therapies (if applicable):
    - ☐ Corticosteroids: \_\_\_\_\_
    - ☐ Long-acting beta 2 agonist: \_\_\_\_\_
    - ☐ Long-acting muscarinic antagonist: \_\_\_\_\_
    - ☐ Immunosuppressants (EGPA): \_\_\_\_\_
  - ☐ **Asthma:** Does the patient have a history of two or more exacerbations requiring a course of oral or systemic corticosteroids, hospitalization or emergency room visit within a 12-month period?  
☐ Yes ☐ No
  - ☐ **Asthma:** Does the patient have an ACQ score consistently greater than 1.5 or ACT score consistently less than 120? ☐ Yes ☐ No
  - ☐ **Primary Immunodeficiency:** Documentation of recurrent bacterial infections, history or failure to respond to antibiotics, documentation of pre and post pneumococcal vaccine titers
- ☐ Include labs and/or test results to support diagnosis (**attach results**)
  - ☐ Does patient have a baseline peripheral blood eosinophil level of  $\geq 150$  cells/mcL within the past 6 weeks (*asthma & EGPA*) or  $\geq 1000$  cells/mcL within 4 weeks (*HES*)? ☐ Yes ☐ No
  - ☐ FEV1 score (if applicable): \_\_\_\_\_
  - ☐ Serum IgE level – *for asthma & nasal polyps Xolair*
  - ☐ Skin/RAST test – *for asthma Xolair*
  - ☐ Serum immunoglobulins – *for Immunoglobulin therapy*
  - ☐ Serum creatinine – *for Immunoglobulin therapy*
  - ☐ CBC w/ differential – *for Fasenra, Nucala, Cinqair*
- ☐ **Xolair – Patient has EpiPen prescribed**
- ☐ Other medical necessity: \_\_\_\_\_

**Please fax all information to 240-892-3005 or email to [info@activeinfusions.com](mailto:info@activeinfusions.com) for assistance**

ACTIVEINFUSIONS.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.